Wed, Apr 16, 2014, 2:13 AM EDT - U.S. Markets open in 7 hrs 17 mins

Recent

% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

rmsacc 526 posts  |  Last Activity: 8 hours ago Member since: Apr 24, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • This just might be one to take in, IMHO.....................good luck to All

  • rmsacc rmsacc Apr 5, 2014 4:35 PM Flag

    Very simply wild, simply a vote to amend Corporate articles. Unless I am mistaken The company has some consideration for their shareholders. Keeping in mind Frost and a few other 5%+ owners are perhaps a major part in that consideration. That is good for them and good for us I think.

    Cauwenbergh has been around the block many times. Keep that in mind.........good luck All

  • CAMBRIDGE — The head of the US agency that approves medicines Friday called for more regulatory flexibility and “a new era of partnership” with the biopharmaceutical industry in bringing new treatments to patients.

    “We see this model emerging where we don’t just wait for an application to come to us,” Food and Drug Administration commissioner Margaret Hamburg told more than 300 drug-making executives at the annual meeting of the Massachusetts Biotechnology Council trade group. “We engage with you early and work with you throughout the development process.”

    Hamburg said the partnership promised “swifter, more efficient product development and product review” after years of criticism from the industry that the drug approval process was too long and cumbersome. FDA officials last year added a “breakthrough therapy” designation to its arsenal of programs meant to accelerate the review of drugs that address pressing unmet medical needs and improve the communications between drug companies and regulators.

    Together, the programs can help cut three to five years off the research and development cycle and months off approval times for new drugs, she said.

    “We are working hard to find ways to decrease the time between discovery, research, and approval,” Hamburg told her audience at the Royal Sonesta Hotel. “It matters to all of you, but it especially matters to patients.” Less

  • rmsacc rmsacc Apr 5, 2014 12:11 PM Flag

    thanks. anybody thinking of attending this meeting ?......................................

  • CAMBRIDGE — The head of the US agency that approves medicines Friday called for more regulatory flexibility and “a new era of partnership” with the biopharmaceutical industry in bringing new treatments to patients.

    “We see this model emerging where we don’t just wait for an application to come to us,” Food and Drug Administration commissioner Margaret Hamburg told more than 300 drug-making executives at the annual meeting of the Massachusetts Biotechnology Council trade group. “We engage with you early and work with you throughout the development process.”

    Hamburg said the partnership promised “swifter, more efficient product development and product review” after years of criticism from the industry that the drug approval process was too long and cumbersome. FDA officials last year added a “breakthrough therapy” designation to its arsenal of programs meant to accelerate the review of drugs that address pressing unmet medical needs and improve the communications between drug companies and regulators.

    Together, the programs can help cut three to five years off the research and development cycle and months off approval times for new drugs, she said.

    “We are working hard to find ways to decrease the time between discovery, research, and approval,” Hamburg told her audience at the Royal Sonesta Hotel. “It matters to all of you, but it especially matters to patients.”

  • Reply to

    Some crunching while we wait

    by helpme_hanna Apr 4, 2014 12:19 PM
    rmsacc rmsacc Apr 4, 2014 6:21 PM Flag

    hanna, the rest of the earlier mssg on this thread:
    As for your very appropriate metaphor of "hitching your wagon to this guy", my guess is that this may have been the very thought of Dr. Frost et.al. I would bet that he did a lot of scouting before he hitched his wagon.

    Most is banked on rx-109 for the near term no doubt, but you make a good point as to the value added to this company with optical, liver, and sd. Add to that the vast estate of patented RNAi compounds inherited last year which were put into the hands of one of a very few companies that have the ability to effectively deliver them.

    I believe RXI's scrap value is greater than their current market cap..............tough week GLA Less

  • Reply to

    Some crunching while we wait

    by helpme_hanna Apr 4, 2014 12:19 PM
    rmsacc rmsacc Apr 4, 2014 5:49 PM Flag

    Thanks orchid, sent email to the few, please give your take........many thanks.

  • Reply to

    Some crunching while we wait

    by helpme_hanna Apr 4, 2014 12:19 PM
    rmsacc rmsacc Apr 4, 2014 4:32 PM Flag

    orchid, very low volume all the way down, product of bio collapse? no doubt to a degree. Very low float did not help the cause. No excuse, but things have not changed. That is to say they are getting dragged down. Very different than results of a failing company. On the contrary I am as
    impressed with progress and the moves of the CEO as I ever was.

    Taking into account the volatility of the industry, as we all witnessed in the hammering we took, long term is the play here. You know that better than I, as I am aware of your experience.

    How are the flowers?.........................until then.

  • Reply to

    Some crunching while we wait

    by helpme_hanna Apr 4, 2014 12:19 PM
    rmsacc rmsacc Apr 4, 2014 1:46 PM Flag

    hanna in the event you erred in your tallies by 80% you won't cry will you?

    As for your very appropriate metaphor of "hitching your wagon to this guy", my guess is that this may have been the very thought of Dr. Frost et.al. I would bet that he did a lot of scouting before he hitched his wagon.

    Most is banked on rx-109 for the near term no doubt, but you make a good point as to the value added to this company with optical, liver, and sd. Add to that the vast estate of patented RNAi compounds inherited last year which were put into the hands of one of a very few companies that have the ability to effectively deliver them.

    I believe RXI's scrap value is greater than their current market cap..............tough week GLA

  • Reply to

    dog days

    by etschell Apr 4, 2014 9:53 AM
    rmsacc rmsacc Apr 4, 2014 11:41 AM Flag

    So, now we wait..................

  • rmsacc rmsacc Apr 3, 2014 6:08 PM Flag

    you're very popular iva_moron...........

  • My bet is there is very good reason why Dr. Frost (specialty; dermatology along with Cauwenbergh), turned over the entire RNAi IP assets over to RXI, along with a $16M investment to boot. Twelve families of patented compounds, many of which may lend themselves to RXI's proprietary delivery technology.

    This alone speaks volumes in that Dr. Frost, biotech assets in the billions, put his money on Dr. Cauwenbergh versus the multitude of other companies in the RNAi field.

    Just another reminder to myself why I did the same...................We're in good hands.

  • rmsacc rmsacc Apr 2, 2014 4:42 PM Flag

    etchell, this is exactly why the entire RNAi IP estate of Opko was handed over to RXI. With a $16M investment to boot. Dr. Frost was in the same field (dermatology). Is it any wonder why he chose Dr. Cauwenbergh's company for the task?

    His track past history and track record precede him. These are individuals who know the industry inside and out. They are not in it for either the salaries not the exercise, If you know what I mean.

    Good luck All...

  • He served at Johnson & Johnson (in both the U.S. and Europe) Consumer and Personal Care Products Companies from 2000 to 2002, where Dr. Cauwenbergh served as Vice President of Technology, where he created technology platforms based on intellectual property and know-how owned by it and developed a business proposition around these platforms as the basis for new companies or new businesses within or outside it.

    Sound familiar? I thought so.....................good luck All

  • Reply to

    Some light reading;

    by rmsacc Mar 31, 2014 1:17 PM
    rmsacc rmsacc Apr 2, 2014 10:26 AM Flag

    hanna, I could not have said it better myself. My guess is you're not just another pretty face.....................good luck All

  • Funds required to step up their pipeline, greater market cap=more exposure, more employees=expedited research (hence the new expanded headquarters this month). It is time.

    Dr. Cauwebergh is no stranger to advancing a developmental company, he has done it many times before.
    He has taken all the right steps with RXI in my opinion, we are in very good hands.........................good luck All

  • rmsacc rmsacc Apr 1, 2014 5:31 PM Flag

    Thanks hanna. No surprise, we knew this was coming. The necessary evils of growing biotech. Dr. Cauwenbergh is very experienced in all financial aspects as can be seen in the expanded profile I posted yesterday. We are in good hands.

    Further confirmation of much bigger plans, Agree, will be interesting to see method of the raise.

    good luck All

  • rmsacc rmsacc Apr 1, 2014 5:19 PM Flag

    golong, link to that news? thanks

  • rmsacc rmsacc Apr 1, 2014 4:36 PM Flag

    blibleess, You have yet to answer the questions for the board;

    "What is RNAi ?" and "Who discovered it?" Take your time they're hard questions.

    You see blibliblis, The entire MB knows that you are a hedge fund lackey idiot. good luck All

  • New York, NY – (NISMAGAZINE) – 03/31/2014 – In this article we are focusing on RXi Pharmaceuticals Corp (NASDAQ:RXII) and Superconductor Technologies, Inc. (NASDAQ:SCON).

    The $53 million market capped drug maker disclosed recently that it would be participating in the “6th Ocular Diseases and Drug Development Conference” in addition to its participation at the American Academy of Dermatology conference which will be holding its 72nd session. The drug maker has also confirmed its participation at the Keystone Symposia Meeting being hosted by Fibrosis. The ocular conference would be held on 20th March at San Diego and the company would be represented by Dr. Cauwenbergh.

    He will surprise us.................................good luck All

IRWD
10.33+0.62(+6.39%)Apr 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Citigroup Inc.
NYSETue, Apr 15, 2014 4:00 PM EDT
Herbalife Ltd.
NYSETue, Apr 15, 2014 4:01 PM EDT
Conns Inc.
NasdaqGSTue, Apr 15, 2014 4:00 PM EDT